A torn tendon and an inflamed gut are not the same problem and should not receive the same protocol. This tool routes by injury: which peptide fits, whether it goes local or systemic, oral or injected, loading or maintenance, plus the cycle timeline and exact reconstitution units.
BPC-157 injected near the injury concentrates it in the damaged tissue. TB-500 runs systemically alongside for whole-body repair signalling.
Educational estimate built from animal data and reported protocols, not medical advice, not a prescription, and not a claim these peptides are proven or approved for these uses in humans. Doses are conservative starting points to discuss with a qualified clinician.
BPC-157 is commonly injected subcutaneously near the injured tissue on the theory that local concentration helps, though animal data shows systemic effects regardless of site. For gut conditions the oral route is preferred, since the arginate salt survives stomach acid and makes direct contact with the tissue you are treating.
TB-500 is systemic. It distributes throughout the body no matter where you inject it, which means injecting it into a painful joint achieves nothing beyond irritating the joint. This is the single most common mistake with the compound. Inject into the abdomen or thigh and rotate sites.
BPC-157 is dosed in micrograms and TB-500 in milligrams, roughly an eightfold to tenfold difference in volume for typical protocols. Two vials both labelled five milligrams therefore require very different draws. Anyone drawing the same units from both is badly underdosing the TB-500. The tool solves each vial separately and flags the gap, using the same backwards-solving approach as the Peptide Reconstitution Calculator.
Both compounds rest on animal studies and user reports rather than human trials. BPC-157 appears on the FDA's Category 2 bulk substances list. That does not mean they do nothing, but it does mean confidence should be moderate, purity matters enormously, and nobody should present these as established medicine. See both entries, graded honestly, alongside every other compound in The Peptide Database.
One caution deserves emphasis: both promote angiogenesis and cell proliferation. Anyone with an active or prior cancer diagnosis should avoid them or discuss with an oncologist first. If your protocol also includes growth hormone peptides, time the injections using the GH Peptide Pulse Optimiser to avoid conflicting with meals or sleep.
Commonly around 250 to 500 micrograms daily, scaled loosely to bodyweight, often split into two doses because the half life is short. Loading protocols use higher doses for the first week to ten days before dropping to maintenance.
For musculoskeletal injuries, subcutaneously near the injured area, not into the joint or tendon itself. For gut issues, the oral arginate form is preferred. For general or systemic use, subcutaneously into the abdomen.
No. TB-500 works systemically and distributes throughout the body regardless of injection site. Injecting it into a sore joint is a common and pointless mistake. Use the abdomen or thigh and rotate sites.
Typically four to eight weeks, extending to around twelve for gut protocols, followed by time off. Neither compound is hormonal, so no taper is physiologically necessary.
They are frequently combined, with BPC-157 dosed daily and TB-500 dosed twice weekly during a loading phase then reduced. Just make sure each vial is reconstituted and calculated separately, since their dose scales differ by roughly an order of magnitude.
